Vivani Medical Completes Phase 1 SLIM-1 Dosing of NPM-139 Implant
ALAMEDA, Calif., August 6, 2026 Vivani Medical, Inc. announced the successful full enrollment and initial dosing of all 20...
Bio-Pharma
Advertisement
Annexon Reports Rapid GBS Responses with Tanruprubart in FORWARD Study
BRISBANE, Calif., August 6, 2026 Annexon, Inc. announced encouraging early clinical results from the ongoing FORWARD open-label study, with...
SciSparc Subsidiary NeuroThera Launches Phase IIb Trial of SCI-110 for Tourette Syndrome
TEL AVIV, Israel, Aug. 5, 2026 SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. has initiated a...
Leads Biolabs’ Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051
NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...
Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
Advertisements
Insilico Medicine Nominates AI-Designed ISM9077 as Preclinical Candidate for Ocular Diseases
HONG KONG, August 5, 2026 Insilico Medicine has announced the nomination of ISM9077 as its 32nd Preclinical Candidate (PCC)...
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine
CAMBRIDGE, Mass., Aug. 5, 2026 Moderna, Inc. has received U.S. Food and Drug Administration (FDA) approval for mFLUSIVA® (mRNA-1010),...
Dianthus Unveils DNTH312 Dual-Target Autoimmune Therapy
NEW YORK and WALTHAM, Mass., August 4, 2026 Dianthus Therapeutics, Inc. announced the launch of DNTH312, an internally developed...
Nurix and Sanofi Advance Oral STAT6 Degrader into Phase 1 Clinical Development
BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...
Pathos AI Partners with AstraZeneca to Advance AZD4241 for ER+ Breast Cancer
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
Advertisement
